Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction

2019 ◽  
Vol 108 (12) ◽  
pp. 1394-1405 ◽  
Author(s):  
Xiaojing Chen ◽  
Gianluigi Savarese ◽  
Ulf Dahlström ◽  
Lars H. Lund ◽  
Michael Fu
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Clinical Phenotype ◽  
Preserved Ejection Fraction ◽  
Age Dependent

scholarly journals Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction

2017 ◽  
Author(s):  
Evandro Tinoco Mesquita ◽  
Antonio José Lagoeiro Jorge ◽  
Celso Vale Souza Junior ◽  
Thais Ribeiro de Andrade
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Cardiac Amyloidosis ◽  
Clinical Phenotype ◽  
Preserved Ejection Fraction

scholarly journals Prevalence, Clinical Phenotype, and Outcomes Associated With Normal B-Type Natriuretic Peptide Levels in Heart Failure With Preserved Ejection Fraction

2012 ◽  
Vol 110 (6) ◽  
pp. 870-876 ◽  
Author(s):  
Venkatesh Y. Anjan ◽  
Timothy M. Loftus ◽  
Michael A. Burke ◽  
Nausheen Akhter ◽  
Gregg C. Fonarow ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Natriuretic Peptide ◽  
Clinical Phenotype ◽  
Preserved Ejection Fraction

Acute heart failure with preserved ejection fraction and long-term Readmisions

2008 ◽  
Vol 7 ◽  
pp. 62-63
Author(s):  
J NUNEZ ◽  
L MAINAR ◽  
G MINANA ◽  
R ROBLES ◽  
J SANCHIS ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Acute Heart Failure ◽  
Preserved Ejection Fraction

Galectin-3 in Heart Failure – Linking Fibrosis, Remodelling and Progression

2010 ◽  
Vol 6 (2) ◽  
pp. 33 ◽  
Author(s):  
Christopher R deFilippi ◽  
G Michael Felker ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Risk Stratification ◽  
Cardiac Fibrosis ◽  
The Elderly ◽  
Preserved Ejection Fraction ◽  
Heart Failure Patients ◽  
Large Populations ◽  
Galectin 3

For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodelling that represents an intriguing link between inflammation and fibrosis. In this article we review the biology of galectin-3, recent clinical research and its application in the management of heart failure patients.

Sign in / Sign up

Export Citation Format

Share Document